The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised


About Elusys Therapeutics

Elusys Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using Heteropolymer (HP) Antibodies for the treatment of infectious disease. The company's Heteropolymer Antibody Technology has demonstrated a ability to clear and destroy pathogens and aims to provide a platform to develop a deep pipeline of drug candidates targeted against bacterial, viral and fungal infections.On December 21st, 2021, Elusys Therapeutics was acquired by Heat Biologics. The terms of the transaction were not disclosed.

Elusys Therapeutics Headquarter Location

25 Riverside Drive 25 Riverside Drive

Pine Brook, New Jersey, 07058,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Elusys Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elusys Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Elusys Therapeutics Patents

Elusys Therapeutics has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Ion channel toxins, Bacterial toxins, Neurotoxins, Invertebrate toxins


Application Date


Grant Date



Related Topics

Transcription factors, Ion channel toxins, Bacterial toxins, Neurotoxins, Invertebrate toxins



Latest Elusys Therapeutics News

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today

May 3, 2022

Morrisville, North Carolina, UNITED STATES DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has completed its name change from Heat Biologics, Inc. to NightHawk Biosciences, Inc. to better reflect the Company’s evolution, including expansion of the therapeutic pipeline, vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company’s new biodefense capabilities. In connection with the name change, the Company’s ticker will change to “NHWK,” effective today, May 3, 2022. The name and symbol changes do not affect the Company's share structure or the rights of the Company's shareholders, and no further action is required by existing shareholders. Jeff Wolf, CEO of Nighthawk, commented, “The NightHawk brand better reflects our evolution towards a fully integrated ecosystem, designed to efficiently move drugs from discovery through commercialization. The NightHawk ecosystem includes an expanded development pipeline, new biodefense capabilities and enhanced manufacturing capabilities. As a result, we have organized the Company around five key subsidiaries: Skunkworx Bio , Heat Biologics , Pelican Therapeutics , Elusys Therapeutics and Scorpion Biological Services . NightHawk is laser focused on addressing key industry challenges, including the slow pace and high cost of new drug development through a fully integrated ecosystem of drug discovery, preclinical testing and manufacturing. We look forward to progressing these efforts under the NightHawk banner.” NightHawk Biosciences, Inc. NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization. The Company leverages its integrated ecosystem of subsidiaries to accelerate the creation and manufacture of novel therapies that arm the immune system, breaking through barriers that prolong traditional drug development. This empowers us to bring our ideas to life with efficient control, superior quality, and uncharacteristic agility. For more information on the Company and is subsidiaries, please visit: , and also follow us on  Twitter . Forward Looking Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements progressing the company’s efforts under the NightHawk banner. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to progress the company’s efforts under the NightHawk banner, the ability to complete to successfully integrate the changes being made, whether the combined business of NightHawk and Elusys will be successful, NightHawk’s and its subsidiaries’ ability to maintain license agreements, the continued maintenance and growth of NightHawk’s and its subsidiaries’ patent estates, NightHawk’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results, the ability to initiate clinical trials and if initiated, the ability to complete them on time and achieve the desired results and benefits continuing enrollment as expected, the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to NightHawk’s ability to promote or commercialize its product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of NightHawk’s , developments by competitors that render such products obsolete or non-competitive, and other factors described in NightHawk’s annual report on Form 10-K for the year ended December 31, 2021, subsequent quarterly reports on Form 10-Qs and any other filings NightHawk makes with the SEC. The information in this presentation is provided only as of the date presented, and NightHawk undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law. Media and Investor Relations Contact David Waldman

  • When was Elusys Therapeutics founded?

    Elusys Therapeutics was founded in 1998.

  • Where is Elusys Therapeutics's headquarters?

    Elusys Therapeutics's headquarters is located at 25 Riverside Drive, Pine Brook.

  • What is Elusys Therapeutics's latest funding round?

    Elusys Therapeutics's latest funding round is Acquired.

  • How much did Elusys Therapeutics raise?

    Elusys Therapeutics raised a total of $65.32M.

  • Who are the investors of Elusys Therapeutics?

    Investors of Elusys Therapeutics include Nighthawk Biosciences, Eagle Advisors, MedImmune Ventures, Crescendo Ventures, Invesco Private Capital and 4 more.

  • Who are Elusys Therapeutics's competitors?

    Competitors of Elusys Therapeutics include Sagimet Biosciences, GangaGen, Innate Pharma, Calibrant Biosystems, Arcion Therapeutics and 15 more.

You May Also Like

Athersys Logo

Athersys develops biotechnology-based therapeutics.


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.


Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing biotherapeutics based on its unique proprietary technology platforms: Affibody molecules and Albumod. The company is based in Solna, Sweden.


Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Pulmotect Logo

Pulmotect is a biopharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.